In these studies, administration of a specific NKG2D blocking antibody decreased NKG2D expression on CD4+ T cells, blocked the receptor on the other lymphocyte subsets and attenuated the development of colitis, highlighting NKG2D as a possible therapeutic target in IBD [9,10]. The gene discussed is CD4; the disease is colitis.